

# Profiling of gene expression regulated by 17 $\beta$ -estradiol and tamoxifen in estrogen receptor-positive and estrogen receptor-negative human breast cancer cell lines

Nelson Rangel<sup>1,2</sup>  
Victoria E Villegas<sup>2</sup>  
Milena Rondón-Lagos<sup>3</sup>

<sup>1</sup>Department of Medical Sciences, University of Turin, Turin, Italy; <sup>2</sup>Faculty of Natural Sciences and Mathematics, Universidad del Rosario, Bogotá, Colombia; <sup>3</sup>School of Biological Sciences, Universidad Pedagógica y Tecnológica de Colombia, Tunja, Colombia

**Abstract:** One area of great importance in breast cancer (BC) research is the study of gene expression regulated by both estrogenic and antiestrogenic agents. Although many studies have been performed in this area, most of them have only addressed the effects of 17 $\beta$ -estradiol (E2) and tamoxifen (TAM) on MCF7 cells. This study aimed to determine the effect of low doses of E2 and TAM on the expression levels of 84 key genes, which are commonly involved in breast carcinogenesis, in four BC cell lines differentially expressing estrogen receptor (ER)  $\alpha$  and HER2 (MCF7, T47D, BT474, and SKBR3). The results allowed us to determine the expression patterns modulated by E2 and TAM in ER $\alpha$ + and ER $\alpha$ - cell lines, as well as to identify differences in expression patterns. Although the MCF7 cell line is the most frequently used model to determine gene expression profiles in response to E2 and TAM, the changes in gene expression patterns identified in ER $\alpha$ + and ER $\alpha$ - cell lines could reflect distinctive properties of these cells. Our results could provide important markers to be validated in BC patient samples, and subsequently used for predicting the outcome in ER $\alpha$ + and ER $\alpha$ - tumors after TAM or hormonal therapy. Considering that BC is a molecularly heterogeneous disease, it is important to understand how well, and which cell lines, best model that diversity.

**Keywords:** breast cancer, cell lines, 17 $\beta$ -estradiol, tamoxifen, ER $\alpha$ +, ER $\alpha$ -, qPCR

## Introduction

Breast cancer (BC) is the most common cancer in women,<sup>1</sup> which has been associated with high exposure to 17 $\beta$ -estradiol (E2). E2 is the main estrogenic hormone, playing an important regulatory role in biological processes such as mammary epithelial cell proliferation and breast development during sexual maturity.<sup>2</sup> The pleiotropic effects of E2 on its target tissues are mediated via its receptors, estrogen receptor (ER)  $\alpha$  and  $\beta$ , which are members of the nuclear receptor superfamily of ligand-activated transcription factors.<sup>3</sup> E2 induces well-established mechanisms to either activate or suppress transcription of its target genes, such as direct interaction with DNA at estrogen response elements,<sup>4</sup> through transcription factor cross talk,<sup>5</sup> and non-genomic mechanisms whereby E2 binds to ERs localized in the cell membrane and activates signal transduction pathways.<sup>6</sup>

The ability of ERs to regulate transcription is also dependent on the nature of their ligands with various natural and synthetic selective ER modulators acting as either ER agonists or ER antagonists.<sup>7,8</sup> One of them is tamoxifen (TAM), a well-known nonsteroidal antiestrogen with partial agonistic activity, which is extensively used in

Correspondence: Milena Rondón-Lagos  
School of Biological Sciences, Universidad Pedagógica y Tecnológica de Colombia, Avenida Central del Norte 39-115, Tunja 150003, Colombia  
Tel +57 8 740 5626  
Email sandra.rondon01@uptc.edu.co

Victoria E Villegas  
Faculty of Natural Sciences and Mathematics, Universidad del Rosario, Carrera 24 N° 63C-69, Bogotá 11001000, Colombia  
Tel +57 1 297 0200 (Extension 4029)  
Fax +57 1 297 0200  
Email victoria.villegas@urosario.edu.co

the treatment of ER $\alpha$ + BC. Although ER $\alpha$  positivity is a well-established predictor of responses to TAM with ER $\alpha$ - patients considered as nonresponders, it is known that 5–10% of ER $\alpha$ - tumors benefit from adjuvant TAM treatment.<sup>9–11</sup> However, responses to TAM have frequently limited durations due to the development of resistance.<sup>12,13</sup>

The MCF7 BC cell line is one of the most widely used models to study estrogen signaling, because the cells express high levels of ER $\alpha$  and their growth is strongly stimulated by E2 in vitro and in xenografts models.<sup>14,15</sup> Considering these aspects, several studies have evaluated gene expression profiles, which focused on identifying changes in gene expression associated with BC prognoses,<sup>16–19</sup> drug resistance,<sup>20</sup> or tumor aggressiveness.<sup>21</sup> Nonetheless, relatively few studies have evaluated gene expression profiles in other ER $\alpha$ + (T47D and BT474) or ER $\alpha$ - (SKBR3) BC cell lines. Similarly, the number of studies that have evaluated the effect of TAM on the gene expression profiles in these cell lines is limited.

Considering that different cell lines with similar immunophenotypes are used in basic and clinical BC research, identification and comparison of genes and genetic pathways responsive to E2 and TAM are necessary to understand the complex effects of these agents on BC cells. This study aimed to determine the effects of low doses of E2 and TAM (0.01 and 1  $\mu$ M, respectively) on the expression levels of 84 key genes, which are commonly involved in the regulation of signal transduction and other biological processes related to breast carcinogenesis in ER $\alpha$ + (MCF7, T47D, and BT474) and ER $\alpha$ - (SKBR3) BC cell lines.

The expression patterns of E2- and TAM-regulated genes identified in ER $\alpha$ + and ER $\alpha$ - cell lines allowed the identification of variations in gene responses to E2 and suggested genes that might serve as markers of sensitivity and/or resistance to TAM. We found that the expression patterns of some of the genes evaluated in this study clearly discriminate ER $\alpha$ + and ER $\alpha$ - BC cell lines.

## Materials and methods

### Cell culture

Human BC cell lines MCF7 (ER $\alpha$ + /HER2-), T47D (ER $\alpha$ + /HER2-), BT474 (ER $\alpha$ + /HER2+), and SKBR3 (ER $\alpha$ - /HER2+) were obtained from the American Type Culture Collection (Manassas, VA, USA). MCF7, T47D, and SKBR3 cells were cultured in RPMI 1640 medium (Sigma, St. Louis, MO, USA), whereas BT474 cells were cultured in Dulbecco's modified Eagle's medium (Sigma). All culture media were supplemented with 10% fetal bovine serum (FBS) (Sigma), antibiotic-antimycotic solution (1X) (Sigma), and 2 mM

L-glutamine (Thermo Fisher Scientific, Waltham, MA, USA). Cells were maintained at 37°C and 5% CO<sub>2</sub>. Absence of mycoplasma contamination was verified by conventional PCR assays.

### E2 and TAM treatments

At 48 h prior to the addition of E2 (E2758; Sigma) or TAM (T5648; Sigma), culture media were changed to phenol red-free RPMI 1640 (Sigma) containing 10% charcoal-stripped FBS (Sigma) to remove endogenous serum steroids and eliminate the weak estrogen agonistic activity of phenol red.<sup>22</sup> E2 and TAM were dissolved in absolute ethanol, diluted in the medium at 0.01 and 1  $\mu$ M, respectively, and then applied to cells for 24 and 48 h. Each time course experiment was carried out in triplicate. RNA was extracted in all cases and used for cDNA synthesis and quantitative real-time PCR (qPCR) assays. Cells without treatment were used as controls.

### RNA extraction

Cell lines were collected in 1 ml TRIZOL Reagent<sup>®</sup> (Ambion; Thermo Fisher Scientific), and RNA extraction was performed according to the manufacturer's instructions. Briefly, total RNA was separated by addition of chloroform, followed by precipitation with isopropanol and 75% ethanol. RNA pellets were resuspended in diethyl pyrocarbonate-treated water (Ambion; Thermo Fisher Scientific) and quantified by spectrophotometry using a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific). RNA was further purified using RNeasy MinElute Cleanup columns (SABiosciences<sup>™</sup>; Qiagen, Hilden, Germany) and treated with an RNase-Free DNase Set (SABiosciences<sup>™</sup>; Qiagen) to remove contaminating genomic DNA. Purified RNA samples were stored at -80°C until analysis.

### Reverse transcription and qPCR

One microgram of RNA, extracted from cell lines treated with either E2 or TAM for 24 and 48 h, was used to synthesize cDNA with an RT<sup>2</sup> First Strand Kit (SABiosciences<sup>™</sup>; Qiagen) according to the manufacturer's instructions. The cDNA for each qPCR array test was combined with ready-to-use RT<sup>2</sup> SYBR Green qPCR Master Mix (SABiosciences<sup>™</sup>; Qiagen), and equal aliquots of this mixture (25  $\mu$ L) were added to each well of a Human Breast Cancer RT<sup>2</sup> Profiler<sup>™</sup> PCR Array plate (PAHS-131A, SABiosciences<sup>™</sup>; Qiagen). This PCR array plate contained gene-specific primer sets for 96 genes including 84 genes associated with breast carcinogenesis, five reference genes (*B2M*, *HPRT1*, *RPL13A*, *GAPDH*, and *ACTB*), one genomic DNA control, three reverse transcription

controls, and three positive PCR controls (Table 1). cDNA was amplified using an iCycler<sup>®</sup> Real-Time PCR System (Bio-Rad Laboratories, Hercules, CA, USA) for 40 cycles (95°C for 15 s and 60°C for 1 min). The threshold cycle (Ct) values were used to calculate the fold changes (FCs) in gene expression (treated cells vs controls – untreated cells) using the PCR array data analysis software (SABiosciences<sup>™</sup>; Qiagen), which was based on the  $2^{-\Delta\Delta C_t}$  method. Gene expression was classified as significantly regulated by E2 or TAM treatments when the FC in expression was at least  $\pm 2$ . qPCR experiments were carried out in three biological replicates, and from each biological replicate, two technical replicates were also performed. The results shown are the average of all the experiments performed.

## Heatmaps of differentially expressed genes (DEGs)

Significant ( $P < 0.05$ ) DEGs (FC:  $\pm 2$ ) were selected to graphically evaluate the activation or inhibition of gene expression in each treated cell line. Genes were clustering using the gplots package from the Bioconductor project.<sup>23</sup> Euclidean distance was used to calculate the matrix of distances, and clusters were generated using Ward's method.

## Biological interpretation of the DEGs (pathway analysis)

Pathway enrichment analysis was conducted by over-representation analysis (ORA). ORA was performed in DAVID Bioinformatics Resources 6.7 of the National Institute of Allergy and Infectious Diseases (National Institutes of Health, Rockville, MD, USA)<sup>24</sup> by employing a pre-filtered list of DEGs. Overrepresented pathways were generated based on the information in the Gene Ontology (GO) project compared with a background limited to the genes analyzed in this study (84 genes). Fisher's exact test was performed to determine the likelihood of obtaining at least equivalent numbers of genes by an actual overlap between the input gene set and the genes in each identified GO category.

## Overall representation of the data

To obtain a simultaneously general representation of the gene expression response of the variously treated cell lines, principal component analysis (PCA) was performed with FCs of all evaluated genes. Because the FC is a ratio of the expression level with a specific treatment and the expression level without treatment, a reference time point for all experimental groups was created (control time 0, FC=1 for all genes). PCA is a linear projection method and an unsupervised exploratory technique used to remove noise, reduce dimensionality, and identify common/dominant signals oriented to find biological meaning. The two principal components (PCs) with the highest degree of variance were plotted. PCA was performed with the prcomp package, and the plot was drawn with gplots, both from the Bioconductor project.<sup>23</sup>

To identify the main genes responsible for the different PC segments, we used the pcaGoPromoter package<sup>25</sup> implemented in R and part of the Bioconductor project. This methodology allows identification of the loading genes in each PC. Additionally, it quantifies the importance of the genes in the reduced predictor. Hansen et al<sup>25</sup> empirically showed that between 0.5 and 8.5% of the total genes is the window to perform the selection of loading genes for good and stable ORA. In this study, a 5% threshold was selected (five genes).

## Statistical analysis

Student's *t*-test was performed to determine significant differences in FC values between groups (treated and untreated cells). *P*-values of  $< 0.05$  (\*) and  $0.01$  (\*\*) were considered as statistically significant. All tables and graphs show the mean values of three independent experiments.

## Results

### Gene expression patterns in BC cell lines treated with E2

In MCF7 cells, 19 out of 84 analyzed genes were regulated by E2 at 24 and/or 48 h (22.6%). Among these genes, 47.4% (n=9) were induced and 52.6% (n=10) were suppressed (Table 2 and Figure 1A). These modulated genes were

**Table 1** Array layout of genes in the Human Breast Cancer RT<sup>2</sup> Profiler<sup>™</sup> PCR Array plate (PAHS-131A, SABiosciences<sup>™</sup>)

|         |       |        |       |        |        |       |        |        |          |        |       |
|---------|-------|--------|-------|--------|--------|-------|--------|--------|----------|--------|-------|
| ABCBI   | ABCG2 | ADAM23 | AKT1  | APC    | AR     | ATM   | BAD    | BCL2   | BIRC5    | BRCA1  | BRCA2 |
| CCNA1   | CCND1 | CCND2  | CCNE1 | CDH1   | CDH13  | CDK2  | CDKN1A | CDKN1C | CDKN2A   | CSF1   | CST6  |
| CTNNA1  | CTSD  | EGF    | EGFR  | ERBB2  | ESR1   | ESR2  | FOXA1  | GATA3  | GLI1     | GRB7   | GSTP1 |
| HIC1    | IDI1  | IGF1   | IGF1R | IGFBP3 | IL6    | JUN   | KRT18  | KRT19  | KRT5     | KRT8   | MAPK1 |
| MAPK3   | MAPK8 | MGMT   | MKI67 | MLH1   | MMP2   | MMP9  | MUC1   | MYC    | NME1     | NOTCH1 | NR3C1 |
| PGR     | PLAU  | PRDM2  | PTEN  | PTGS2  | PYCARD | RARB  | RASSF1 | RB1    | SERPINE1 | SFN    | SFRP1 |
| SLC39A6 | SLIT2 | SNAI2  | SRC   | TFF3   | TGFB1  | THBS1 | TP53   | TP73   | TWIST1   | VEGFA  | XBPI  |
| B2M     | HPRT1 | RPL13A | GAPDH | ACTB   | HGDC   | RTC   | RTC    | RTC    | PPC      | PPC    | PPC   |

**Table 2** List of E2-regulated genes in MCF7, T47D, BT474, and SKBR3 cells

| Cell line | 24 h      | 48 h          | Gene name       | GenBank no.    | Pattern expression |       |
|-----------|-----------|---------------|-----------------|----------------|--------------------|-------|
| MCF7      | 3.4822**  | 1.8025        | <i>BIRC5</i>    | NM_001168      | Early              |       |
|           | 2.1435*   | 1.7411        | <i>NME1</i>     | NM_000269      |                    |       |
|           | -2.4623   | -1.2311       | <i>SERPINE1</i> | NM_000602      | Early and late     |       |
|           | 2.4623**  | 2.639**       | <i>BRCA1</i>    | NM_007294      |                    |       |
|           | 3.249**   | 2.3784**      | <i>BRCA2</i>    | NM_000059      |                    |       |
|           | -2**      | -2.0705**     | <i>CCND2</i>    | NM_001759      |                    |       |
|           | 3.4822*   | 5.0982**      | <i>EGF</i>      | NM_001963      |                    |       |
|           | 2.8284**  | 2.4623**      | <i>HPRT1</i>    | NM_000194      |                    |       |
|           | -3.0314   | -2.0705       | <i>TWIST1</i>   | NM_000474      |                    |       |
|           | -2.4623   | -2.4623       | <i>ERBB2</i>    | NM_004448      |                    |       |
|           | -2.8945   | -3.1383       | <i>GRB7</i>     | NM_005310      |                    |       |
|           | -2.639**  | -5.0982**     | <i>IGFBP3</i>   | NM_000598      |                    |       |
|           | 3.249**   | 2.0705**      | <i>MKI67</i>    | NM_002417      | Late               |       |
|           | 6.0629**  | 8.8766**      | <i>PGR</i>      | NM_000926      |                    |       |
|           | -2.1435** | -2.2191**     | <i>RARB</i>     | NM_000965      |                    |       |
|           | -2.639**  | -3.7321**     | <i>SLIT2</i>    | NM_004787      |                    |       |
|           | 1.7613    | 2.5491**      | <i>TFF3</i>     | NM_003226      |                    |       |
|           | -1.7211   | -2.1435**     | <i>NR3C1</i>    | NM_000176      |                    |       |
|           | -1.7211   | -2.2974**     | <i>CDKN1A</i>   | NM_000389      |                    |       |
|           | 2.9794**  | 1.9656        | <i>BRCA1</i>    | NM_007294      |                    | Early |
| 2.7678*   | 1.9571    | <i>CCNE1</i>  | NM_001238       |                |                    |       |
| 2.1067**  | 1.7715    | <i>PGR</i>    | NM_000926       | Early and late |                    |       |
| 2.9409    | 1.8742    | <i>TP73</i>   | NM_005427       |                |                    |       |
| 2.6735    | 2.3274    | <i>ABCG2</i>  | NM_004827       |                |                    |       |
| 2.0885*   | 2.4837*   | <i>BIRC5</i>  | NM_001168       |                |                    |       |
| 2.3784**  | 5.278**   | <i>MYC</i>    | NM_002467       |                |                    |       |
| 2.2482**  | 2.4095**  | <i>BRCA2</i>  | NM_000059       |                |                    |       |
| 2.3784    | 2.3784    | <i>SFN</i>    | NM_006142       |                |                    |       |
| 2.2875    | 2.2095    | <i>SRC</i>    | NM_005417       |                |                    |       |
| 2.7203    | 3.716**   | <i>ESR2</i>   | NM_001437       |                |                    |       |
| 1.858     | 2.7203**  | <i>MKI67</i>  | NM_002417       |                | Late               |       |
| 1.5223    | 2.0795    | <i>NOTCH1</i> | NM_017617       |                |                    |       |
| 1.9487    | 2.0885    | <i>RASSF1</i> | NM_007182       |                |                    |       |
| 1.3779    | 3.3782*   | <i>TGFB1</i>  | NM_000660       |                |                    |       |
| 1.3899    | 2.2579**  | <i>THBS1</i>  | NM_003246       |                |                    |       |
| 1.5422    | 2.2776    | <i>CTSD</i>   | NM_001909       |                |                    |       |
| BT474     | -2.5669*  | -1.3013       | <i>SNAI2</i>    | NM_003068      |                    | Early |
|           | 2.2815**  | 1.8277        | <i>NME1</i>     | NM_000269      |                    |       |
|           | 3.1167**  | 3.6553**      | <i>THBS1</i>    | NM_003246      | Early and late     |       |
|           | -2.5669   | -2.7895       | <i>GATA3</i>    | NM_002051      |                    |       |
|           | 3.1167**  | 2.8679**      | <i>IGF1R</i>    | NM_000875      |                    |       |
|           | -2.4794** | -3.9449**     | <i>EGFR</i>     | NM_005228      |                    |       |
|           | -4.9588   | -2.8879       | <i>IGFBP3</i>   | NM_000598      |                    |       |
|           | 25.8125** | 15.1369**     | <i>MYC</i>      | NM_002467      |                    |       |
|           | 9.1261**  | 9.3179**      | <i>PGR</i>      | NM_000926      |                    |       |
|           | -2.3134*  | -2.6945*      | <i>MUC1</i>     | NM_001018016   |                    |       |
|           | -2.2346   | -2.042        | <i>SLIT2</i>    | NM_004787      |                    |       |
|           | -1.7532   | -2.514        | <i>ERBB2</i>    | NM_004448      |                    | Late  |
|           | -1.3287   | -2.114        | <i>ESR1</i>     | NM_000125      |                    |       |
|           | -1.4743   | -2.2658       | <i>FOXA1</i>    | NM_004496      |                    |       |
|           | -1.5263   | -2.114*       | <i>GRB7</i>     | NM_005310      |                    |       |
|           | -1.0792   | -2.042*       | <i>GSTP1</i>    | NM_000852      |                    |       |
|           | -1.815    | -2.042**      | <i>NR3C1</i>    | NM_000176      |                    |       |
| 1.3566    | 4.0558**  | <i>ABCG2</i>  | NM_004827       |                |                    |       |

(Continued)

**Table 2** (Continued)

| Cell line | 24 h      | 48 h      | Gene name       | GenBank no.  | Pattern expression |
|-----------|-----------|-----------|-----------------|--------------|--------------------|
| SKBR3     | 2.0849    | 1.1096    | <i>BAD</i>      | NM_004322    | Early              |
|           | 2.0849*   | 1.1096    | <i>BRCA2</i>    | NM_000059    |                    |
|           | 3.7581**  | 1.366     | <i>CCNE1</i>    | NM_001238    |                    |
|           | 3.2716    | 1.366     | <i>IGFBP3</i>   | NM_000598    |                    |
|           | 5.1337**  | 1.4142    | <i>IL6</i>      | NM_000600    |                    |
|           | -2.4453** | -1.2746   | <i>MUC1</i>     | NM_001018016 |                    |
|           | 2.8481*   | 1.9319    | <i>PLAU</i>     | NM_002658    |                    |
|           | -2.1287   | -1.0718   | <i>PYCARD</i>   | NM_013258    |                    |
|           | 2.395     | 1.1096    | <i>SERPINE1</i> | NM_000602    |                    |
|           | -2.1287*  | -2.2974** | <i>CDKN1C</i>   | NM_000076    |                    |
|           | 4.0278    | 2.1435**  | <i>BCL2</i>     | NM_000633    | Late               |
|           | 1.3566    | 2.2191**  | <i>CDHI</i>     | NM_004360    |                    |

**Note:** Values are fold changes of  $\pm 2$  at each time point relative to control with the statistically significant values indicated by asterisks (\* $P < 0.05$  and \*\* $P < 0.01$ ).

**Abbreviation:** E2, 17 $\beta$ -estradiol.

assigned to one of three patterns: genes regulated at 24 h only (early expression; 15.8%), genes regulated at 24 and 48 h (early and late expression; 68.4%), and genes regulated at 48 h only (late expression; 15.8%). Cluster analysis demonstrated two patterns of modulated gene expression at both time points: upregulated (first cluster) and downregulated (second cluster) (Figure 1A). Among the 19 genes regulated by E2 in MCF7 cells, *BIRC5*, *NME1*, *BRCA1*, *BRCA2*, *EGF*, *HPRT1*, *MKI67*, *PGR*, and *TFF3* were upregulated significantly ( $P < 0.05$ ), while *CCND2*, *IGFBP3*, *RARB*, *SLIT2*, *NR3C1*, and *CDKN1A* genes were downregulated significantly (Table 2).

In T47D cells, expressions of 17 out of the 84 analyzed genes were modulated at 24 and/or 48 h (20.2%). In contrast to MCF7 cells, all E2-regulated genes were upregulated (Table 2 and Figure 1B). Among these genes, four (23.5%) showed early expression, six (35.3%) showed early and late expression, and seven (41.25%) showed late expression. Cluster analysis demonstrated three patterns of modulated gene expression with the first cluster including genes with early and late expression, the second cluster including genes regulated at both 24 and 48 h, and the third cluster corresponding to genes mostly regulated at 48 h (Figure 1B). Significantly altered expression ( $P < 0.05$ ) was observed in 10 (*BRCA1*, *CCNE1*, *PGR*, *BIRC5*, *MYC*, *BRCA2*, *ESR2*, *MKI67*, *TGFB1*, and *THBS1*) out of 17 genes (58.8%) upregulated by E2 in T47D cells (Table 2).


In BT474 cells, 18 out of the 84 analyzed genes (21.4%) were regulated by E2 at 24 and/or 48 h. Six (33.3%) were induced, while 12 (66.6%) were suppressed (Table 2 and Figure 1C). Among these genes, two (11.11%) showed early expression, nine (50%) showed early and late expression, and seven (38.88%) showed late expression. Similar to MCF7 cells, cluster analysis demonstrated two patterns of modulated

gene expression with the first cluster including upregulated genes and the second cluster including downregulated genes at both examined time points (Figure 1C). However, it is important to note that, in contrast to MCF7 cells, most genes (six out of seven) were suppressed at 48 h (late expression). Twelve genes were regulated significantly ( $P < 0.05$ ) by E2 in BT474 cells: *NME1*, *THBS1*, *IGF1R*, *MYC*, *PGR*, and *ABCG2* were upregulated, while *SNAI2*, *EGFR*, *MUC1*, *GRB7*, *GSTP1*, and *NR3C1* were downregulated (Table 2).

In SKBR3 (ER $\alpha$ -) cells, E2 treatment resulted in the lowest number of modulated genes, 12 out of 84 (14.3%). Among them, nine (75%) were induced and three (25%) were suppressed (Table 2 and Figure 1D). In contrast to the other cell lines, most genes (nine) underwent early regulation at 24 h only. Cluster analysis demonstrated three patterns of modulated gene expression: upregulated genes (FC:  $>3$ ) with an early response, upregulated genes (FC:  $<3$ ) with an early response, and downregulated genes with an early response (Figure 1D). Among the 12 genes regulated by E2, six were significantly upregulated (*BRCA2*, *CCNE1*, *IL6*, *PLAU*, *BCL2*, and *CDHI*), while the significantly downregulated genes included *MUC1* and *CDKN1C* (Table 2).

## Gene expression patterns in BC cell lines treated with TAM

The number of TAM-regulated genes was lower compared with the E2 response in all cell lines. In MCF7 cells, five out of 84 analyzed genes (5.95%) changed their pattern of expression at 24 and/or 48 h: two of them were induced, while 3 were suppressed (Table 3 and Figure 2A). Only in MCF7 cells, at least one gene was seen in each of the three patterns: three genes showed early expression, one gene showed early and late expression, and one gene showed late expression.



**Figure 1** Cluster analysis of the time course of E2-regulated gene expression in (A) MCF7, (B) T47D, (C) BT474, and (D) SKBR3 cells. Gene cluster analysis was performed for 84 genes after E2 exposure at 24 and 48 h. The threshold cycle ( $C_t$ ) values were used to calculate the FCs in gene expression (treated cells vs controls – untreated cells) using the PCR array data analysis software (SABiosciences™), which was based on the  $2^{-\Delta\Delta C_t}$  method. Significant differentially expressed genes ( $FC \geq \pm 2$ ;  $P < 0.05$ ) were selected to graphically evaluate the activation or inhibition of gene expression in each treated cell line. Induced genes are shown in red, suppressed genes in green, and unregulated genes in black.

**Abbreviations:** E2, 17 $\beta$ -estradiol; FC, fold change.

Only *PGR* and *EGF* (40%) showed significant increases in expression ( $P < 0.05$ ).

Conversely, T47D was a cell line in which a smaller effect was seen after TAM addition. Only three out of the 84 analyzed genes were regulated (3.6%), and all of them were upregulated only at 24 h (Table 3 and Figure 2B). None of these three genes showed statistically significant differences in expression.

BT474 was the cell line in which TAM showed a higher effect; 11 out of 84 analyzed genes were regulated (13.1%): one gene (9.1%) was upregulated, while the other 10 genes (90.9%) were suppressed (Table 3 and Figure 2C). In addition, the expression of all of these genes was modified only at later time point (48 h). Among these genes, four (36.3%) showed statistically significant altered expression: three were

**Table 3** List of genes up- or downregulated (negative values) by TAM in MCF7, T47D, BT474, and SKBR3 cells

| Cell line | 24 h     | 48 h      | Gene name       | GenBank no.  | Pattern expression |           |       |
|-----------|----------|-----------|-----------------|--------------|--------------------|-----------|-------|
| MCF7      | -2.3784  | -1.7613   | <i>CDKN1C</i>   | NM_000076    | Early              |           |       |
|           | -2.0705  | -1.6434   | <i>CSF1</i>     | NM_000757    |                    |           |       |
|           | 3.1383*  | 1.977     | <i>PGR</i>      | NM_000926    |                    |           |       |
|           | 4.2871** | 3.6893**  | <i>EGF</i>      | NM_001963    | Early and late     |           |       |
|           | -1.366   | -2.0232   | <i>SERPINE1</i> | NM_000602    | Late               |           |       |
| T47D      | 2.3681   | 1.9235    | <i>GATA3</i>    | NM_002051    | Early              |           |       |
|           | 2.4516   | 1.3601    | <i>RARB</i>     | NM_000965    |                    |           |       |
|           | 2.2677   | 1.2152    | <i>TWIST1</i>   | NM_000474    |                    |           |       |
| BT474     | -1.2746  | -2.4284** | <i>EGFR</i>     | NM_005228    | Late               |           |       |
|           | -1.5157  | -2.6027   | <i>ERBB2</i>    | NM_004448    |                    |           |       |
|           | -1.7411  | -2.3457   | <i>GATA3</i>    | NM_002051    |                    |           |       |
|           | -1.1892  | -2.114    | <i>GRB7</i>     | NM_005310    |                    |           |       |
|           | -1.1096  | -2.114**  | <i>JUN</i>      | NM_002228    |                    |           |       |
|           | -1.2311  | -2.3457   | <i>NOTCH1</i>   | NM_017617    |                    |           |       |
|           | 1.8025   | 2.6759*   | <i>PGR</i>      | NM_000926    |                    |           |       |
|           | -1.4641  | -2.6945   | <i>RASSF1</i>   | NM_007182    |                    |           |       |
|           | -1.2746  | -2.1886   | <i>SRC</i>      | NM_005417    |                    |           |       |
|           | -1.2746  | -2.9897   | <i>CDKN1C</i>   | NM_000076    |                    |           |       |
|           | -1.1892  | -3.3173** | <i>VEGFA</i>    | NM_003376    |                    |           |       |
|           | SKBR3    | 2.2191    | 1.0792          | <i>BAD</i>   |                    | NM_004322 | Early |
|           |          | 2.639     | 1.2658          | <i>CCNE1</i> |                    | NM_001238 |       |
| 2         |          | 1.0281    | <i>IGFBP3</i>   | NM_000598    |                    |           |       |
| -2.0705*  |          | -1.5583   | <i>MUC1</i>     | NM_001018016 |                    |           |       |

**Note:** Values are fold changes of  $\pm 2$  at each time point relative to control with the statistically significant values indicated by asterisks (\* $P < 0.05$  and \*\* $P < 0.01$ )

**Abbreviation:** TAM, tamoxifen.

downregulated (*EGFR*, *JUN*, and *VEGFA*), and one (*PGR*) was upregulated.

Finally, TAM effects on SKBR3 cells were slight, modulating four out of the 84 analyzed genes (4.8%) at 24 h (early expression): three of them were upregulated and one gene was downregulated (Table 3 and Figure 2D). Only the *MUC1* gene showed statistically significant downregulation relative to the control.


### Pathway analysis of E2-regulated genes

To further evaluate data at the biological level, pathway analysis was conducted by ORA. Table 4 lists biological pathways overrepresented after E2 addition with pathways in which the expression levels of significantly modulated genes were changed with respect to those that would be expected to change by chance.

In MCF7 cells, E2 stimulated the expression of genes associated with the cell cycle process and DNA replication (*BRCA2*, *BIRC5*, *EGF*, and *BRCA1*). The *BIRC5* gene encoding survivin is a member of the inhibitor of apoptosis gene family that encodes negative regulatory proteins that prevent apoptotic cell death. Amplification of this gene has been reported in 15–30% of BCs, and it has been shown to predict the distant recurrence.<sup>26</sup> Similarly, overexpression of *BRCA1*

and *BRCA2* genes can cause an aberrant response to DNA damage. Thus, upregulation of these genes probably leads to an overall increase in both proliferation and cell survival. Conversely, addition of E2 to MCF7 cells suppressed genes involved in regulation of cell development (*IGFBP3* and *SLIT2*), and apoptosis activation and cell death (*CDKN1A*, *MMP9*, *RARB*, *NR3C1*, and *IGFBP3*). The *IGFBP3* gene has antiproliferative effects on cancer. It is involved in the repair of DNA damage in BC cells<sup>27</sup> and controls cell growth by feedback.<sup>28</sup> In addition, deregulation or loss of *IGFBP3* gene expression has been associated with other carcinomas,<sup>29</sup> whereas the *SLIT2* gene possesses a suppressive activity against cancer metastasis.<sup>30</sup> Deregulation of genes implicated in apoptosis activation and cell death might be related to the increased cell proliferation observed in these cells and could favor tumor development.

In T47D cells, there were several genes upregulated by E2 with known relevant oncogenic functions. Here, we could observe differences in pathway activation according to treatment time points. Thus, at 24 h, E2 activated genes related to signaling pathways of steroid hormones and regulation of transcription (*PGR*, *CCNE1*, *BRCA2*, *ESR2*, *MYC*, and *BRCA1*), while at 48 h, E2 activated genes related to regulation of the cell cycle process and response to abi-



**Figure 2** Cluster analysis of the time course of TAM-regulated gene expression in (A) MCF7, (B) T47D, (C) BT474, and (D) SKBR3 cells. Gene cluster analysis was performed for 84 genes after TAM exposure at 24 and 48 h. The threshold cycle (Ct) values were used to calculate the FCs in gene expression (treated cells vs controls – untreated cells) using the PCR array data analysis software (SABiosciences™), which was based on the  $2^{-\Delta\Delta C_t}$  method. Significant differentially expressed genes (FC=±2;  $P<0.05$ ) were selected to graphically evaluate the activation or inhibition of gene expression in each treated cell line. Induced genes are shown in red, suppressed genes in green, and unregulated genes in black.

**Abbreviations:** TAM, tamoxifen; FC, fold change.

otic stimulus (*MKI67*, *BRCA2*, *BIRC5*, *THBS1*, *MYC*, and *TGFBI*) (Table 4).

Genes preferentially upregulated by E2 in BT474 cells encode proteins with diverse roles in multiple functional pathways including positive regulation of molecular functions (*NME1*, *THBS1*, and *MYC*) and antiapoptosis (*IGF1R*, *THBS1*, and *MYC*) (Table 4). *NME1* is involved in cell

proliferation and differentiation, and its high expression has been associated with sporadic colorectal cancer.<sup>31</sup> The *THBS1* gene encodes a glycoprotein that mediates cell-to-cell and cell-to-matrix interactions, and has been shown to play roles in the promotion of angiogenesis and metastasis of invasive ductal BC.<sup>32</sup> The *MYC* gene encodes a protein that promotes cell cycle progression, apoptosis, and cellular transformation.

**Table 4** List of biological pathways overrepresented by up- or downregulated genes in MCF7, T47D, BT474, and SKBR3 cells after E2 treatments

| Cell line            | Time | Signal pathways                                   | Genes   | FE    | P (Fisher) |
|----------------------|------|---|---|-------|------------|
| <b>Upregulated</b>   |      |   |   |       |            |
| MCF7                 | 24 h | Regulation of cell cycle process                  | <i>BRCA2, BIRC5, EGF, BRCA1</i>               | 4.7   | 3.30E-03   |
|                      | 24 h | DNA replication                                   | <i>BRCA2, EGF, BRCA1</i>                      | 7.1   | 3.50E-03   |
|                      | 48 h | DNA replication                                   | <i>BRCA2, EGF, BRCA1</i>                      | 8.3   | 2.10E-03   |
| T47D                 | 24 h | Steroid hormone receptor signaling pathway        | <i>PGR, CCNE1, ESR2, BRCA1</i>                | 5.3   | 2.10E-03   |
|                      | 24 h | Intracellular receptor-mediated signaling pathway | <i>PGR, CCNE1, ESR2, BRCA1</i>                | 5.3   | 2.10E-03   |
|                      | 24 h | Regulation of transcription                       | <i>PGR, CCNE1, BRCA2, ESR2, MYC, BRCA1</i>    | 2     | 2.00E-02   |
|                      | 24 h | Cell cycle process                                | <i>CCNE1, BRCA2, BIRC5, MYC, BRCA1</i>        | 2.3   | 2.90E-02   |
|                      | 48 h | Cell cycle process                                | <i>MKI67, BRCA2, BIRC5, THBS1, MYC, TGFB1</i> | 2.7   | 3.30E-03   |
|                      | 48 h | Cell cycle  | <i>MKI67, BRCA2, BIRC5, THBS1, MYC, TGFB1</i> | 2.5   | 6.60E-03   |
|                      | 48 h | Antiapoptosis                                     | <i>BIRC5, ESR2, THBS1, MYC</i>                | 3.6   | 1.00E-02   |
|                      | 48 h | Response to abiotic stimulus                      | <i>BRCA2, THBS1, MYC, TGFB1</i>               | 3.2   | 1.80E-02   |
|                      | 48 h | Regulation of mitotic cell cycle                  | <i>BRCA2, BIRC5, MYC, TGFB1</i>               | 3.2   | 1.80E-02   |
| BT474                | 24 h | Positive regulation of molecular function         | <i>NME1, THBS1, MYC</i>                       | 3.9   | 2.10E-02   |
|                      | 48 h | Antiapoptosis                                     | <i>IGF1R, THBS1, MYC</i>                      | 4.8   | 1.10E-02   |
| SKBR3                | 24 h | Developmental growth                              | <i>CCNE1, BRCA2, PLAU</i>                     | 6.9   | 3.50E-03   |
|                      | 24 h | Growth  | <i>CCNE1, BRCA2, PLAU</i>                     | 5.7   | 6.60E-03   |
|                      | 48 h | Response to toxin                                 | <i>BCL2, CDH1</i>                             | 27.77 | 8.80E-04   |
| <b>Downregulated</b> |      |   |   |       |            |
| MCF7                 | 24 h | Regulation of cell development                    | <i>IGFBP3, SLIT2</i>                          | 6.2   | 5.50E-03   |
|                      | 48 h | Positive regulation of apoptosis                  | <i>CDKN1A, MMP9, RARB, NR3C1, IGFBP3</i>      | 2.2   | 3.40E-02   |
|                      | 48 h | Positive regulation of cell death                 | <i>CDKN1A, MMP9, RARB, NR3C1, IGFBP3</i>      | 2.2   | 3.40E-02   |
|                      | 48 h | Positive regulation of programmed cell death      | <i>CDKN1A, MMP9, RARB, NR3C1, IGFBP3</i>      | 2.2   | 3.40E-02   |

**Notes:** Pathway analysis was conducted via ORA. ORA was performed in DAVID Bioinformatics Resources 6.7 of the National Institute of Allergy and Infectious Diseases (National Institutes of Health).<sup>24</sup> Pathways listed include those whose differentially expressed genes were significantly altered after 24 and 48 h of E2 treatment.

**Abbreviations:** E2, 17 $\beta$ -estradiol; FE, fold enrichment; ORA, overrepresentation analysis.

Mutations, overexpression, rearrangement, and translocation of this gene have been observed in various tumors.<sup>33</sup> Elevated expression levels of the *IGF1R* gene have been associated with poor survival of patients with invasive BC<sup>34</sup> and TAM resistance in xenograft models.<sup>35</sup>

In SKBR3 cells, E2 caused upregulation of genes associated with growth (*CCNE1*, *BRCA2*, and *PLAU*) and responses to toxins (*BCL2* and *CDH1*). These signaling pathways are involved in positive regulation of cell migration, proliferation, and apoptosis, and all of them correlate with carcinogenesis. Of note, *BCL2* is one of the most important antiapoptotic genes and widely related to survival of tumor cells. *CCNE1* is an important regulator of cell cycle progression, and its overexpression has been associated with poor overall survival and BC-specific survival.<sup>36</sup> *PLAU* encodes a serine protease involved in degradation of the extracellular matrix and possibly tumor cell migration and proliferation.<sup>37</sup>


Notably, in BT474 and SKBR3 cells, genes downregulated by E2 were not found to be significantly associated with any particular signaling pathway. The number of significantly modulated genes by TAM was insufficient to establish any

association with a particular signaling pathway in any of the studied cell lines.

## Overall representation of the data (PCA)

For a simultaneously general representation of the gene expression response in treated cell lines, PCA was performed (Figure 3). After 24 and 48 h of E2 treatment, MCF7 and BT474 cells had the most diverse conditions, differing in the direction of the positive and negative parts of PC1 compared with the control (time 0). Interestingly, the E2 response was also different in BT474 and MCF7 cells according to the position in PC2 (positive and negative parts). TAM-treated cells had a lesser difference compared with the control (time 0). The largest response after TAM treatment for 24 and 48 h was found in MCF7 cells. However, significant differences were not observed between cell lines. In general, T47D and SKBR3 cell lines had a lesser response in all experimental conditions (Figure 3).

The *pcaGoPromoter* package<sup>25</sup> was used to identify genes responsible for the differences (loading genes) in each PC (Figure 3). PC1 positive describes the lesser response to TAM in most treated cell lines and E2 response in SKBR3



**Figure 3** PCA of MCF7, T47D, BT474, and SKBR3 cells after E2 and TAM treatments. PCA was performed for all evaluated genes (84 genes) compared with time 0. Thus grouped, after 24 and 48 h of E2 treatment, MCF7 and BT474 cells showed most diverse conditions compared with the control (time 0) and also between them, differing in the direction of the PC1 and PC2, respectively, while after TAM treatment, the cells had a lesser difference compared with the control (time 0). The largest response after TAM treatment for 24 and 48 h was found in MCF7 cells. Each cell line is represented by a different color, and each treatment performed is represented by a different geometric figure.

**Abbreviations:** PCA, principal component analysis; E2, 17 $\beta$ -estradiol; TAM, tamoxifen; PC, principal component.

and T47D cells. The top five genes involved in the positive part were *CCNE1*, *BCL2*, *BAD*, *PTGS2*, and *GLI1*. PC1 negative and PC2 positive describe the common E2 response in MCF7 and BT474 cells in which the top five genes involved were *PGR*, *MYC*, *IGFBP3*, *THBS1*, and *EGFR*. However, the specific E2 response in BT474 cells could be explained by the positive part of PC2, in which the top five genes involved were *MYC*, *IGF1R*, *THBS1*, *EGFR*, and *MUC1* (FC:  $\pm 2$  and  $P < 0.05$ ; Table 2). Conversely, the specific E2 response in MCF7 cells was explained by the negative part of PC2, in which the top five genes involved were *EGF*, *CSF1*, *BRCA2*, *CDKN1C*, and *IGFBP3* (FC:  $\pm 2$  and  $P < 0.05$ ; Table 2).

## Discussion

One area of great importance in BC research is the study of gene expression regulated by both estrogenic and antiestrogenic agents. Although many studies have been performed in this area, most of them have only examined the effects of E2 and TAM on MCF7 cells.<sup>14,38-41</sup> In the present study, we analyzed changes in gene expression in not only MCF7 cells

but also other ER $\alpha$ + and ER $\alpha$ - cell lines (T47D, BT474, and SKBR3) for 84 genes related to BC development. This allowed us to determine the expression patterns modulated by E2 and TAM in these cells and perform comparisons between other cell lines and MCF7 cells.

After E2 treatment, several patterns of regulation were apparent: while in MCF7 the number of upregulated and downregulated genes was similar, the majority of them were upregulated in T47D cells, and downregulated in SKBR3 and BT474 cells. After E2 addition to MCF7 cells, we obtained similar results to those reported previously in other studies.<sup>39</sup> Interestingly, genes such as *EGF*, *RARB*, *CCND2*, *IGFBP3*, *SLIT2*, and *HPRT1* were significantly regulated only in this cell line, not only indicating specific signal pathway activation but also revealing that *HPRT1* would not be useful as a reference/housekeeping gene at least in MCF7 cells. The *BIRC5* gene was upregulated in both MCF7 and T47D cells, which confirmed that hormonal regulation of survivin mediated some of the effects of E2 on programmed cell death in ER $\alpha$ + BC cells.<sup>42,43</sup> Other genes that were upregulated in MCF7 and T47D cells after E2 treatment were *MKI67*,

*BRCA1*, *BRCA2*, and *PGR*, which suggest increased cell responses to genomic damage.<sup>39</sup>

Although T47D and MCF7 cells are immunohistochemically similar (ER $\alpha$ +/*HER2*-), we observed differences in regulation of genes such as *c-MYC*, *TGFB1*, and *THSB1*. Nevertheless, although the *c-MYC* gene has been reported to be upregulated by E2 in MCF7 cells,<sup>44</sup> we did not find statistically significant changes in its expression. Conversely, such changes were markedly observed in T47D and BT474 cells.

Similar to MCF7 cells, the BT474 cell line (ER $\alpha$ +/*HER2*+) showed a larger number of changes in gene expression after E2 treatment, and the number of suppressed genes was greater than that of upregulated genes. In addition to the highest upregulation of *c-MYC* and *PGR* genes after E2 treatment, BT474 cells showed specific and important regulation of genes such as *THBS1*, *EGFR*, *IGF1R*, and *MUC1*. Interestingly, genes associated with the *HER2* signaling pathway (*IGFBP3*, *PGR*, *SLIT2*, *ERBB2*, *GRB7*, and *NR3C1*) exhibited the same trend in both MCF7 and BT474 cells, although not significant in all cases, indicating a similar response mediated by ER independently of the *HER2* status.

SKBR3 cells (ER $\alpha$ -/*HER2*+) were clearly different from MCF7 cells, because only the *BRCA2* gene showed a similar expression pattern after E2 treatment. Interestingly, activation of antiapoptotic *BCL2* was specific for SKBR3 cells, and such regulation has been reported as a direct target of transcriptional regulation by ER in MCF7 cells.<sup>45</sup> Although we did not find regulation of *BCL2* in MCF7 cells, these observations strongly support the notion that ER $\alpha$  is not always required for E2 regulation and provide evidence that E2 activates other signaling pathways not associated with ER $\alpha$ . In SKBR3 cells, genes such as *IL6*, *PLAU*, and *CDKN1C* also showed specific and important regulation in at least one of the E2 experimental conditions.

Results from pathway analysis suggested that the gene expression program activated by E2 reflects more than a simple mitogenic response to this hormone in all cell lines. Accordingly, many of the E2-regulated genes were involved in cellular functions other than cell cycle control, such as cell development changes (*SLIT2* and *IGFBP3*) and cell survival (*BIRC5*).<sup>14,43,46</sup> Although the immunohistochemical status allows supposing a similar response to E2 in ER $\alpha$ + BC cell lines (MCF7, T47D, and BT474), PCA showed how ER $\alpha$ + cells behave differently, not only with respect to ER $\alpha$ - cells (SKBR3) but also between them. Accordingly, MCF7 cells exhibited an important activation of DNA replication through genes such as *EGF* and *BRCA2*, whereas in BT474 cells,

mainly antiapoptotic mechanisms were activated through *MYC*, *IGF1R*, and *THSB1* genes.

Even if PCA confirmed that gene expression changes after TAM treatment were not significant to differentiate BC cell lines, a smaller effect was observed and some genes displayed similar expression patterns to those seen after E2 treatment. In three of the tested cell lines, both E2 and TAM modulated the expression of *PGR* and *EGF* in MCF7 and BT474 cells, and *MUC1* in SKBR3 cells. Our results suggest similarities between signaling pathways activated by E2 and TAM. These similarities could be associated with “non-genomic” actions of E2 in target cells, leading to direct hormonal regulation of multiple cytoplasmic signal transductions, as suggested previously.<sup>47-51</sup>

Our results are relevant, because many studies have reported that resistance to TAM may be due to its substantial E2 agonist effect in ER $\alpha$ +/*HER2*+ cells.<sup>48,49,51-53</sup> Similarly, our data indicate that TAM could perform this E2 agonist role in not only ER $\alpha$ +/*HER2*+ (BT474) cells but also both ER $\alpha$ +/*HER2*- (MCF7) and ER $\alpha$ -/*HER2*+ (SKBR3) cells, according to the cellular response (gene expression pattern) triggered by this drug. In fact, recently it has been indicated that in BC patients, the balance between agonist and antagonist properties of TAM differs among cell types, supporting our observations.<sup>54</sup>

Also, it is important to consider that the effects of E2 and TAM on these cells could be explained by genetic heterogeneity among BC cells and also differences in ER $\alpha$  amount. In fact, it has been reported that T47D cells have low levels of ER $\alpha$  compared with MCF7 cells.<sup>55</sup> Additionally, it is necessary to note that other ER forms, such as G protein-coupled estrogen receptor (GPER) and ER $\beta$ , might also be involved in the effects observed after treatments. GPER, an estrogen transmembrane receptor, which modulates both rapid non-genomic and genomic transcriptional events of estrogens, has been observed in ER $\alpha$ + cells (MCF7 and T47D).<sup>56</sup> In addition, recent emerging evidence demonstrated that GPER could be a potential transducer of E2 in SKBR3 cells.<sup>57</sup> Thus, the presence of this receptor could also explain the modulation of gene expression induced by E2 and TAM in all cell lines analyzed. In fact, GPER has been involved in drug resistance, which often occurs during cancer treatments.<sup>58</sup> Otherwise, considering that in human BC cell lines the expression of endogenous ER $\beta$  has not been clearly described,<sup>59</sup> it could be suggested that the modulation of gene expression in ER $\alpha$ + and ER $\alpha$ - cells could be attributed to both ER $\alpha$  and GPER. However, further functional studies are needed to determine if the observed gene expression changes were modulated by ER $\alpha$ , GPER, or both.

Concurrent with our work, some studies identified genes associated with TAM resistance in ER $\alpha$ + BC patients. Interestingly, some of these genes were found modified by TAM in our study, which supports our approach. One of these studies found a low expression of *CDKN1A* after TAM treatment,<sup>20</sup> as found by us in MCF7 cells. *CDKN1A* encodes the protein p21<sup>WAF1/CIP1</sup>; this protein has been reported to be absent in a clinical case of TAM-stimulated growth.<sup>60</sup> p21<sup>WAF1/CIP1</sup> interacts with several cell cycle regulators, but the precise mechanism behind its role in TAM resistance is unclear. Additional studies showed significantly lower expression of *CDKN1C* gene in BC patients treated with adjuvant therapy (TAM)<sup>61</sup> and a high expression of *PGR* gene in TAM-treated patients.<sup>62</sup> Similar results were observed by us in ER $\alpha$ + cell lines (MCF7 and BT474) after TAM addition. *CDKN1C* is a tumor suppressor gene that regulates cell proliferation and has recently been found to be downregulated in metastatic tumors. *PGR* gene encodes a protein that mediates the physiological effects of progesterone, which plays a central role in reproductive events associated with the establishment and maintenance of pregnancy. Interestingly, this gene has recently been considered as one of the most promising prognostic biomarkers in TAM-treated patients.<sup>62</sup>

Taking all together, our results could provide important markers to be validated in BC patient samples, and subsequently used for predicting the outcome in ER $\alpha$ + and ER $\alpha$ - tumors after TAM or hormonal therapy. Exploring novel markers for TAM therapy will be helpful for the treatment of BC.

## Conclusion

Although the MCF7 cell line is the most frequently used model to determine gene expression profiles in response to treatments with E2 and TAM, the changes in gene expression patterns identified in ER $\alpha$ + and ER $\alpha$ - cell lines could reflect distinctive properties of these cells, which could be exploited not only to identify the response of various cell types to E2 but also to examine whether these genes might serve as markers of TAM sensitivity and/or participate in the development of TAM resistance. Indeed, we have shown that the expression patterns of some genes can be used to discriminate between ER $\alpha$ + cells, and between ER $\alpha$ + and ER $\alpha$ - cells.

## Acknowledgments

Nelson Rangel is supported by a Colciencias Grant (call 617, Colombia). The authors acknowledge the scientific support provided by Professor Anna Sapino. César Payán-Gómez is acknowledged for bioinformatic analyses. The authors thank

Mitchell Arico from Edanz Group ([www.edanzediting.com/ac](http://www.edanzediting.com/ac)) for editing the draft of this manuscript.

## Author contributions

Milena Rondón-Lagos and Nelson Rangel conceived and designed the study, and wrote the manuscript. Victoria E Villegas contributed to writing of the manuscript and made critical revisions. All authors contributed toward data analysis, drafting and critically revising the paper and agree to be accountable for all aspects of the work.

## Disclosure

The authors report no conflicts of interest in this work.

## References

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancer base no. 11 [Internet]. Lyon: IARC; 2013. Available from: <http://globocan.iarc.fr>. Accessed February 20, 2017.
2. Platet N, Cathiard AM, Gleizes M, Garcia M. Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. *Crit Rev Oncol Hematol*. 2004;51(1):55–67.
3. Hall JM, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen receptor signaling. *J Biol Chem*. 2001;276(40):36869–36872.
4. Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor transcription and transactivation: estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. *Breast Cancer Res*. 2000;2(5):335–344.
5. Kalaitzidis D, Gilmore TD. Transcription factor cross-talk: the estrogen receptor and NF-kappaB. *Trends Endocrinol Metab*. 2005;16(2):46–52.
6. Sommer S, Fuqua SA. Estrogen receptor and breast cancer. *Semin Cancer Biol*. 2001;11(5):339–352.
7. Katzenellenbogen BS, Katzenellenbogen JA. Biomedicine. Defining the “S” in SERMs. *Science*. 2002;295(5564):2380–2381.
8. Margeat E, Bourdoncle A, Margueron R, Poujol N, Cavaillès V, Royer C. Ligands differentially modulate the protein interactions of the human estrogen receptors alpha and beta. *J Mol Biol*. 2003;326(1):77–92.
9. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. *Lancet*. 1998;351(9114):1451–1467.
10. Gruberger-Saal SK, Bendahl PO, Saal LH, et al. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. *Clin Cancer Res*. 2007;13(7):1987–1994.
11. McGuire WL. Current status of estrogen receptors in human breast cancer. *Cancer*. 1975;36(2):638–644.
12. Pearce ST, Jordan VC. The biological role of estrogen receptors alpha and beta in cancer. *Crit Rev Oncol Hematol*. 2004;50(1):3–22.
13. International Breast Cancer Study Group, Colleoni M, Gelber S, Goldhirsch A, et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. *J Clin Oncol*. 2006;24(9):1332–1341.
14. Frasar J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. *Endocrinology*. 2003;144(10):4562–4574.
15. Creighton CJ, Cordero KE, Larios JM, et al. Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors. *Genome Biol*. 2006;7(4):R28.

16. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. *Nature*. 2000;406(6797):747–752.
17. Jiang Y, Harlocker SL, Molesh DA, et al. Discovery of differentially expressed genes in human breast cancer using subtracted cDNA libraries and cDNA microarrays. *Oncogene*. 2002;21(14):2270–2282.
18. Colombo PE, Milanezi F, Weigelt B, Reis-Filho JS. Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction. *Breast Cancer Res*. 2011;13(3):212.
19. Sheen-Chen SM, Huang CY, Chan YC, et al. An evaluation of focal adhesion kinase in breast cancer by tissue microarrays. *Anticancer Res*. 2013;33(3):1169–1173.
20. Lyng MB, Laenkholm AV, Tan Q, et al. Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study. *PLoS One*. 2013;8(1):e54078.
21. Zajchowski DA, Bartholdi MF, Gong Y, et al. Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. *Cancer Res*. 2001;61(13):5168–5178.
22. Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. *Proc Natl Acad Sci U S A*. 1986;83(8):2496–2500.
23. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. *Genome Biol*. 2004;5(10):R80.
24. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc*. 2009;4(1):44–57.
25. Hansen M, Gerds TA, Nielsen OH, Seidelin JB, Troelsen JT, Olsen J. pcaGoPromoter – an R package for biological and regulatory interpretation of principal components in genome-wide gene expression data. *PLoS One*. 2012;7(2):e32394.
26. Davis LM, Harris C, Tang L, et al. Amplification patterns of three genomic regions predict distant recurrence in breast carcinoma. *J Mol Diagn*. 2007;9(3):327–336.
27. Lin MZ, Marzec KA, Martin JL, Baxter RC. The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents. *Oncogene*. 2014;33(1):85–96.
28. Schedlich LJ, Yenson VM, Baxter RC. TGF- $\beta$ -induced expression of IGFBP-3 regulates IGF1R signaling in human osteosarcoma cells. *Mol Cell Endocrinol*. 2013;377(1–2):56–64.
29. Yin J, Ding J, Huang L, et al. SND1 affects proliferation of hepatocellular carcinoma cell line SMMC-7721 by regulating IGFBP3 expression. *Anat Rec (Hoboken)*. 2013;296(10):1568–1575.
30. Chen WF, Gao WD, Li QL, Zhou PH, Xu MD, Yao LQ. SLIT2 inhibits cell migration in colorectal cancer through the AKT-GSK3 $\beta$  signaling pathway. *Int J Colorectal Dis*. 2013;28(7):933–940.
31. Lin HW, Gao LD, Wei GH. hMSH2 and nm23 expression in sporadic colorectal cancer and its clinical significance. *Asian Pac J Cancer Prev*. 2013;14(3):1995–1998.
32. Horiguchi H, Yamagata S, Rong Qian Z, Kagawa S, Sakashita N. Thrombospondin-1 is highly expressed in desmoplastic components of invasive ductal carcinoma of the breast and associated with lymph node metastasis. *J Med Invest*. 2013;60(1–2):91–96.
33. Ginter PS, Mosquera JM, MacDonald TY, D'Alfonso TM, Rubin MA, Shin SJ. Diagnostic utility of MYC amplification and anti-MYC immunohistochemistry in atypical vascular lesions, primary or radiation-induced mammary angiosarcomas, and primary angiosarcomas of other sites. *Hum Pathol*. 2014;45(4):709–716.
34. Law JH, Habibi G, Hu K, et al. Phosphorylated insulin-like growth factor-*i*/insulin receptor is present in all breast cancer subtypes and is related to poor survival. *Cancer Res*. 2008;68(24):10238–10246.
35. Massarweh S, Osborne CK, Creighton CJ, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. *Cancer Res*. 2008;68(3):826–833.
36. Gao S, Ma JJ, Lu C. Prognostic value of cyclin E expression in breast cancer: a meta-analysis. *Tumour Biol*. 2013;34(6):3423–3430.
37. Ding Y, Zhang H, Zhong M, et al. Clinical significance of the uPA system in gastric cancer with peritoneal metastasis. *Eur J Med Res*. 2013;18(1):28.
38. Bouras T, Southey MC, Chang AC, et al. Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. *Cancer Res*. 2002;62(5):1289–1295.
39. Bourdeau V, Deschênes J, Laperrière D, Aid M, White JH, Mader S. Mechanisms of primary and secondary estrogen target gene regulation in breast cancer cells. *Nucleic Acids Res*. 2008;36(1):76–93.
40. Gadal F, Starzec A, Bozic C, et al. Integrative analysis of gene expression patterns predicts specific modulations of defined cell functions by estrogen and tamoxifen in MCF7 breast cancer cells. *J Mol Endocrinol*. 2005;34(1):61–75.
41. Sadler AJ, Pugazhendhi D, Darbre PD. Use of global gene expression patterns in mechanistic studies of oestrogen action in MCF7 human breast cancer cells. *J Steroid Biochem Mol Biol*. 2009;114(1–2):21–32.
42. Choi KS, Lee TH, Jung MH. Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells. *Cancer Gene Ther*. 2003;10(2):87–95.
43. Buterin T, Koch C, Naegeli H. Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. *Carcinogenesis*. 2006;27(8):1567–1578.
44. Lin Z, Reierstad S, Huang CC, Bulun SE. Novel estrogen receptor- $\alpha$  binding sites and estradiol target genes identified by chromatin immunoprecipitation cloning in breast cancer. *Cancer Res*. 2007;67(10):5017–5024.
45. Perillo B, Sasso A, Abbondanza C, Palumbo G. 17 $\beta$ -estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. *Mol Cell Biol*. 2000;20(8):2890–2901.
46. Chen X, Duan N, Zhang C, Zhang W. Survivin and tumorigenesis: molecular mechanisms and therapeutic strategies. *J Cancer*. 2016;7(3):314–323.
47. Srinivasan S, Nawaz Z. Molecular biology of estrogen receptor action. In: Pfaff DW, Arnold AP, Fahrbach SE, Etgen AM, Rubin RT, editors. *Hormones Brain and Behavior*. 2nd ed. San Diego, CA: Academic Press; 2009:1187–1220.
48. Chang M. Dual roles of estrogen metabolism in mammary carcinogenesis. *BMB Rep*. 2011;44(7):423–434.
49. Pietras RJ, Márquez-Garbán DC. Membrane-associated estrogen receptor signaling pathways in human cancers. *Clin Cancer Res*. 2007;13(16):4672–4676.
50. Song RX, Fan P, Yue W, Chen Y, Santen RJ. Role of receptor complexes in the extranuclear actions of estrogen receptor  $\alpha$  in breast cancer. *Endocr Relat Cancer*. 2006;13(Suppl 1):S3–S13.
51. Kumar R, Zakharov MN, Khan SH, et al. The dynamic structure of the estrogen receptor. *J Amino Acids*. 2011;2011:812540.
52. Drury SC, Detre S, Leary A, et al. Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. *Endocr Relat Cancer*. 2011;18(5):565–577.
53. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. *J Natl Cancer Inst*. 2004;96(12):926–935.
54. Chanrion M, Negre V, Fontaine H, et al. A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. *Clin Cancer Res*. 2008;14(6):1744–1752.
55. Read LD, Keith D Jr, Slamon DJ, Katzenellenbogen BS. Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. *Cancer Res*. 1990;50(13):3947–3951.
56. Samartzis EP, Noske A, Varga Z, Fink D, Imesch P. The G protein-coupled estrogen receptor (GPER) is expressed in two different subcellular localizations reflecting distinct tumor properties in breast cancer. *PLoS One*. 2014;9(1):e83296.
57. Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. *Endocrinology*. 2005;146(2):624–632.

58. Papa A, Caruso D, Tomao S, Rossi L, Zaccarelli E, Tomao F. Triple-negative breast cancer: investigating potential molecular therapeutic target. *Expert Opin Ther Targets*. 2015;19(1):55–75.
59. Haldosén LA, Zhao C, Dahlman-Wright K. Estrogen receptor beta in breast cancer. *Mol Cell Endocrinol*. 2014;382(1):665–672.
60. Abukhdeir AM, Vitolo MI, Argani P, et al. Tamoxifen-stimulated growth of breast cancer due to p21 loss. *Proc Natl Acad Sci U S A*. 2008;105(1):288–293.
61. Pawitan Y, Bjöhle J, Amler L, et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. *Breast Cancer Res*. 2005;7(6):R953–R964.
62. Mihály Z, Kormos M, Lániczky A, et al. A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer. *Breast Cancer Res Treat*. 2013;140(2):219–232.

## Breast Cancer - Targets and Therapy

### Publish your work in this journal

Breast Cancer - Targets and Therapy is an international, peer-reviewed open access journal focusing on breast cancer research, identification of therapeutic targets and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient.

Submit your manuscript here: <https://www.dovepress.com/breast-cancer---targets-and-therapy-journal>

Dovepress

The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.